Latest Regulatory News

Alara Resources’ independently audited reserve statement supports about eight more years of production at its Oman copper mine, with 7.70 million tonnes classified as Probable Ore Reserves. The update also reveals the limits of the mine plan: the licence expires before the scheduled mine life ends, while several technical studies remain unfinished.

Biotron has appointed Glenn Gilbert as chief executive and executive director, bringing more than two decades of pharmaceutical, medical device and diagnostics experience to the company’s SedRx and antiviral programs. His package combines a $250,000 salary with up to 100 million performance-based options and $230,000 in milestone-linked cash bonuses.

Euroz Hartleys says several conditions for its A$145 million sale of the Capital Markets business to BMO have now been satisfied, leaving shareholder approval and Canadian Bank Act approval among the key remaining gates. Completion remains on track for the December quarter.

ReNerve has received supportive FDA feedback on the preclinical and testing pathway for its NervAlign Nerve Guide Matrix. The guidance sharpens the route towards a US submission, but does not amount to clearance and leaves the submission timetable open.

Bubs Australia delivered 9.2% revenue growth and a sharp underlying EBITDA improvement in FY26, but statutory losses, weaker margins and negative operating cash flow expose the cost of its expansion. Permanent US FDA authorisation removes a major regulatory hurdle, while the annual report still flags material uncertainty around ongoing funding and cash generation.

IAG has offered a package of competition remedies to support approval of its proposed 20-year insurance alliance with RAC of Western Australia, including the transfer of NRMA policy renewal rights and a $20 million community investment. The insurer says the transaction still carries $1.2 billion in additional annual gross written premium and approximately $100 million in annual pre-tax synergies once integration is complete.

Elixinol Wellness lifted Q3 gross profit 27% and delivered a fourth consecutive quarter of positive underlying operating cash flow, despite statutory operating cash flow remaining negative and cash below A$1 million. The proposed all-scrip Vitable acquisition could add scale, but shareholder approval and a thin liquidity buffer remain important next tests.

Clever Culture Systems has appointed PSC Biotech as its sole sales agent for APAS Independence across pharmaceutical manufacturing markets in the US, Canada and Singapore. The agreement expands CCS’s reach beyond its direct focus on major global drugmakers, but any material revenue uplift is not expected before FY28.

Tasman Resources has received South Australian approval for its Parkinson Dam environmental programme, clearing the regulatory path for a 20-hole drilling campaign. The programme now hinges on contractor appointments and a drilling start date, with historical high-grade gold and silver results providing the geological rationale.

Condor Energy has secured formal qualification from Peru’s state oil and gas agency, allowing it to negotiate a proposed exploration and exploitation licence for offshore Block Z-72. The milestone moves the project forward, but it is not a final licence award.

Central Asia Metals has secured the Kazakhstan regulatory approval required for its proposed acquisition of Cygnus Metals, removing a key condition before tomorrow’s Second Court Hearing. The scheme remains subject to the court process and any remaining conditions, with implementation still targeted for 27 October.

Zenith Minerals has reaffirmed its support for Forrestania Resources’ takeover, arguing that the completed Edna May acquisition and A$310 million capital raising outweigh a sharply lower implied offer value. The recommendation comes with a clear split: long-term shareholders may favour the combination, while shorter-term holders may reasonably reject it.